| Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma JK Lin, LS Muffly, MA Spinner, JI Barnes, DK Owens, ... Journal of Clinical Oncology, 2105-2119, 2019 | 192 | 2019 |
| Cost-effectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women C Dosiou, J Barnes, A Schwartz, R Negro, L Crapo, A Stagnaro-Green The Journal of Clinical Endocrinology 97 (5), 1536-1546, 2012 | 162 | 2012 |
| Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia JK Lin, BJ Lerman, JI Barnes, BC Boursiquot, YJ Tan, AQL Robinson, ... Journal of clinical oncology 36 (32), 3192-3202, 2018 | 138 | 2018 |
| Characterizing the impact of 25 years of DCIS treatment EM Ozanne, Y Shieh, J Barnes, C Bouzan, ES Hwang, LJ Esserman Breast cancer research and treatment 129, 165-173, 2011 | 128 | 2011 |
| Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p JI Barnes, V Divi, A Begaye, R Wong, S Coutre, DK Owens, ... Blood advances 2 (15), 1946-1956, 2018 | 51 | 2018 |
| A medical risk attitude subscale for DOSPERT S Butler, A Rosman, S Seleski, M Garcia, S Lee, J Barnes, A Schwartz Judgment and Decision Making 7 (2), 189-195, 2012 | 42 | 2012 |
| Risk perception and risk attitudes in Tokyo: A report of the first administration of DOSPERT+ M in Japan A Schwartz, K Yamagishi, N Hirahara, H Onishi, J Barnes, A Rosman, ... Judgment and Decision Making 8 (6), 691-699, 2013 | 25 | 2013 |
| Cost-effectiveness of open versus endoscopic carpal tunnel release JI Barnes, G Paci, T Zhuang, LC Baker, SM Asch, RN Kamal JBJS 103 (4), 343-355, 2021 | 15 | 2021 |
| Patient and health care factors associated with long-term diabetes complications among adults with and without mental health and substance use disorders EM Schmidt, J Barnes, C Chen, J Trafton, S Frayne, AHS Harris JAMA network open 2 (9), e1912060-e1912060, 2019 | 9 | 2019 |
| National trends in the diagnosis of CRPS after open and endoscopic carpal tunnel release K Mertz, J Trunzter, E Wu, J Barnes, SL Eppler, RN Kamal Journal of Wrist Surgery 8 (03), 209-214, 2019 | 9 | 2019 |
| Cost-effectiveness of initial versus delayed lanreotide for treatment of metastatic enteropancreatic neuroendocrine tumors JI Barnes, JK Lin, D Gupta, DK Owens, JD Goldhaber-Fiebert, PL Kunz Journal of the National Comprehensive Cancer Network 18 (9), 1200-1209, 2020 | 4 | 2020 |
| Reducing telemetry use is safe: A retrospective analysis of rapid response team and code events after a successful intervention to reduce telemetry use L Xie, T Garg, D Svec, J Hom, R Kaimal, N Ahuja, J Barnes, L Shieh American Journal of Medical Quality 34 (4), 398-401, 2019 | 4 | 2019 |
| The Medicare drug price negotiation program: Considerations for therapeutic alternatives JK Lin, JI Barnes, JA Doshi Health Affairs Forefront, 2023 | 1 | 2023 |
| EE41 Cost-effectiveness of anti-BCMA CAR T-cell therapy in triple-class refractory multiple myeloma JI Barnes, ZA Frosch, AL Garfall, D Vogl, J Lin Value in Health 25 (7), S343, 2022 | 1 | 2022 |
| The Cost-Effectiveness of Initial vs Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors in the United States JI Barnes, J Lin, DK Owens, JD Goldhaber-Fiebert, PL Kunz PANCREAS 48 (3), 429-429, 2019 | 1 | 2019 |
| Computing the Cost of Care per Patient per Day for Patients With Metastatic Neuroendocrine Neoplasms DM Gupta, J Barnes, FF Qin, K Kapphahn, K Hornbacker, DW Blayney, ... JCO Oncology Practice 20 (2), 203-211, 2024 | | 2024 |
| Arriving At A Fair Price In The Medicare Drug Price Negotiation Program: Considerations From Other Countries JK Lin, JI Barnes, JA Doshi, S Ghabri, P Kolominsky-Rabas, B O’Rourke Health Affairs Forefront, 2023 | | 2023 |
| rapid communication abstract Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma JK Lin, LS Muf, MA Spinner, JI Barnes, DK Owens | | 2019 |
| Calibrating Models of Cancer Treatment to Overall and Progression-Free Survival Curves: Consistently Reflecting Uncertainty and Heterogeneity J Barnes, J Lin, JD Goldhaber-Fiebert 17th Biennial European Conference, 2018 | | 2018 |
| Cost-Effectiveness of Ibrutinib for First-Line Therapy for Chronic Lymphocytic Leukemia JI Barnes, V Divi, DK Owens, S Coutre, JD Goldhaber-Fiebert 39th Annual Meeting of the Society for Medical Decision Making, 2017 | | 2017 |
Jeremy Goldhaber-FiebertStanford UniversityDirección de correo verificada de stanford.edu
